Literature DB >> 30236539

Performance of the point-of-care circulating cathodic antigen (POC-CCA) urine cassette test for follow-up after treatment of S. mansoni infection in Eritrean refugees.

Andreas Neumayr1, Afona Chernet2, Véronique Sydow2, Kerstin Kling2, Esther Kuenzli2, Hanspeter Marti2, Daniel H Paris2, Beatrice Nickel2, Niklaus D Labhardt3.   

Abstract

BACKGROUND: Point-of-care circulating cathodic antigen (POC-CCA) urine cassette testing has become a popular approach to screen for Schistosoma infection. Since the test is also increasingly used for following-up of treatment success, we assessed the assay's diagnostic accuracy after praziquantel treatment of S. mansoni infection among Eritrean refugees in Switzerland.
METHODS: In our preceding study, 107 asymptomatic Eritrean refugees in Switzerland were screened for schistosomiasis by stool microscopy, serology, and POC-CCA urine testing. Individuals screened positive by any method were treated with praziquantel and invited for a follow-up visit, repeating the same diagnostic procedures one year after treatment. The POC-CCA baseline and follow-up results were analyzed against the 'baseline microscopy positive cases' (= the most reliably true positive cases) and the 'baseline microscopy plus serology negative cases at baseline and follow-up' (= the most reliably true negative cases).
RESULTS: Complete diagnostic baseline and follow-up sampling was available from 48 participants. Compared to most reliably true positive cases at baseline, POC-CCA testing had a sensitivity of 90%. Compared to most reliably true negative cases, POC-CCA testing had a specificity of 73.9%.
CONCLUSION: We conclude that the POC-CCA urine test is valuable for screening but its use is not suitable for routine follow-up after treatment.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Migrants; Schistosomiasis; Screening; Specificity; Urine

Mesh:

Substances:

Year:  2018        PMID: 30236539     DOI: 10.1016/j.tmaid.2018.09.004

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  5 in total

Review 1.  The Advances in Molecular and New Point-of-Care (POC) Diagnosis of Schistosomiasis Pre- and Post-praziquantel Use: In the Pursuit of More Reliable Approaches for Low Endemic and Non-endemic Areas.

Authors:  Marta G Cavalcanti; Aline Fernandes Araujo Cunha; José Mauro Peralta
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

2.  Evaluation of microscopy, serology, circulating anodic antigen (CAA), and eosinophil counts for the follow-up of migrants with chronic schistosomiasis: a prospective cohort study.

Authors:  Francesca Tamarozzi; Tamara Ursini; Pytsje T Hoekstra; Ronaldo Silva; Cecilia Costa; Federico Gobbi; Gerardo B Monteiro; Leonardo Motta; Govert J van Dam; Paul L Corstjens; Lisette van Lieshout; Dora Buonfrate
Journal:  Parasit Vectors       Date:  2021-03-09       Impact factor: 3.876

3.  Evaluation of the Point-of-Care Circulating Cathodic Antigen Assay for Monitoring Mass Drug Administration in a Schistosoma mansoni Control Program in Western Kenya.

Authors:  Anne Straily; Emmy A Kavere; Dollycate Wanja; Ryan E Wiegand; Susan P Montgomery; Alex Mwaki; Alie Eleveld; W Evan Secor; Maurice R Odiere
Journal:  Am J Trop Med Hyg       Date:  2021-11-08       Impact factor: 3.707

4.  Sensitive Diagnosis and Post-Treatment Follow-Up of Schistosoma mansoni Infections in Asymptomatic Eritrean Refugees by Circulating Anodic Antigen Detection and Polymerase Chain Reaction.

Authors:  Pytsje T Hoekstra; Afona Chernet; Claudia J de Dood; Eric A T Brienen; Paul L A M Corstjens; Niklaus D Labhardt; Beatrice Nickel; Linda Wammes; Govert J van Dam; Andreas Neumayr; Lisette van Lieshout
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 2.345

5.  Cross-reaction of POC-CCA urine test for detection of Schistosoma mekongi in Lao PDR: a cross-sectional study.

Authors:  Anousin Homsana; Peter Odermatt; Phonesavanh Southisavath; Aya Yajima; Somphou Sayasone
Journal:  Infect Dis Poverty       Date:  2020-08-12       Impact factor: 4.520

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.